US EditionPublished • loading... • Updated
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
AI models integrating imaging, clinical, and molecular data from over 4,300 TAILORx patient samples improve late distant recurrence prediction in hormone receptor-positive breast cancer.
- ECOG-ACRIN and Caris Life Sciences unveiled AI models integrating imaging, clinical, and molecular data at SABCS, reflecting their public-private partnership, with initial findings presented without a specific date.
- Early-Stage breast cancer represents a pressing challenge because it is a large, heterogeneous population making long-term recurrence assessment critical, and the TAILORx trial biorepository provided specimens enabling this research.
- Using 4,462 TAILORx tumor specimens, the team developed and validated multimodal models with a 42-gene expanded M+ panel, trained in NSABP B-42, and validated on the same specimens, demonstrating robust recurrence prediction.
- The research suggests the model can identify patients after a standard five-year course of adjuvant endocrine therapy with minimal recurrence risk who could be spared additional treatment, and it could serve as a scalable, cost-effective alternative to genomic assays using clinicopathologic factors and routine H&E data.
- The press release warns that forward‑looking statements note validation, regulatory and commercialization risks that could impede diagnostic test development despite Caris Life Sciences sequencing and AI platforms and ECOG-ACRIN Group Co-Chair Peter J. O'Dwyer, MD, integrating TAILORx datasets.
Insights by Ground AI
15 Articles
15 Articles
Mason City Globe Gazette+14 Reposted by 14 other sources
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence risk in early-stage breast cancer and guide long-term treatment decisions
Coverage Details
Total News Sources15
Leaning Left1Leaning Right0Center7Last UpdatedBias Distribution87% Center
Bias Distribution
- 87% of the sources are Center
87% Center
13%
C 87%
Factuality
To view factuality data please Upgrade to Premium
